Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talimogene Laherparepvec +/- Nivolumab in Refractory Lymphomas and Rare Skin Tumors
NCT02978625Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2017
- Primary completion
- Sep 2027
- Modality
- Oncolytic Viruses, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talimogene laherparepvec and nivolumab in T-cell lymphoma, natural killer cell lymphoma (NKCL), cutaneous squamous cell carcinoma (cSCC) and 2 more, sponsored by National Cancer Institute. Primary endpoints: Response rate to talimogene laherparepvec alone (Part I) at 1 year and Best overall response rate to talimogene laherparepvec and nivolumab combination therapy (Part II) at 1 year. Started Sep 2017; status: active, not recruiting.
02
Drugs
talimogene laherparepvecnivolumab
03
Conditions
T-cell lymphomanatural killer cell lymphoma (NKCL)cutaneous squamous cell carcinoma (cSCC)Merkel cell carcinoma (MCC)non-melanoma skin cancer (NMSC)
Beyond the preview
Go deeper on NCT02978625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02978625.